tonabacase (LSVT-1701) / Roivant, iNtRON Bio, Basilea - LARVOL DELTA

Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow (GlobeNewswire) - "For the full year (FY) 2024, Basilea recognized total revenue of CHF 208.5m (FY 2023: CHF 157.6m). This included royalty income of CHF 96.7m (FY 2023: CHF 78.9m) from Cresemba, which increased by 22.6% year-on-year, and product revenue of CHF 57.8m (FY 2023: CHF 37.9m), which increased by 52.5% year-on-year...Other revenue amounted to CHF 13.7m (FY 2023: CHF 7.4m). This included CHF 10.2m BARDA reimbursements (FY 2023: CHF 4.2m) for remaining activities related to the phase 3 program for ceftobiprole and under the Other Transaction Agreement (OTA) executed in September 2024. In 2024, Basilea invested CHF 77.1m (FY 2023: CHF 77.9m) in research and development, mainly for the phase 3 program with fosmanogepix, the preclinical profiling of BAL2062 and tonabacase, the acquisition and preclinical activities for the LptA inhibitor program, the remainder of the phase 3 ceftobiprole program and for research work on compounds in the Company’s early-stage portfolio."

Commercial • Infectious Disease • Pneumonia

Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow (GlobeNewswire) - "In 2025, we will focus on further advancing our portfolio, first by starting the second phase 3 study with our potential next lead product, fosmanogepix, in mold infections. In addition, we are continuing the preclinical work with the antifungal BAL2062 and the LptA inhibitor antibiotic, BAL2420, in preparation for the subsequent clinical studies, planned to start in 2026. For the early-stage asset tonabacase, we have completed our pre-clinical profiling and taken the decision not to pursue further development."

Discontinued • New P3 trial • Candidiasis • Infectious Disease

Bacteriophages as a potential substitute for antibiotics: A comprehensive review. (PubMed, Cell Biochem Funct) - "Many commercially available endolysins such as Staphefekt SA.100, Exebacase (CF-301), and N-Rephasin®SAL200 are used in biofilm penetration and treating plant diseases. Although obtaining commercial approval may be time-consuming, it will be beneficial in the postantibiotic era. This review provides an overview of the significance of phage therapy as a potential alternative to antibiotics in combating resistant bacterial strains and its application to various fields and emphasizes the importance of safeguarding and ensuring treatment efficacy."

Journal • Review • Infectious Disease

ERASE: ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Lysovant | N=12 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Cardiovascular

ERASE: ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis (clinicaltrials.gov) - P2 | N=12 | Recruiting | Sponsor: Lysovant | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular

ERASE: ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis (clinicaltrials.gov) - P2 | N=12 | Not yet recruiting | Sponsor: Lysovant

New P2 trial • Cardiovascular